Poster (Scientific congresses and symposiums)
c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds
Lemaitre, Florence; Chakrama, Fatima; Dequiedt, Franck et al.
2021Joint Course on Post-Transcriptional Gene Regulation and Genome Instability
 

Files


Full Text
poster FL_MC_avril 2021.pdf
Publisher postprint (1.11 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
alternative splicing; cisplatin; c-Jun and RBM39
Abstract :
[en] Cisplatin-based chemotherapy remains frequently used to treat a wide range of solid tumors, but intrinsic and acquired resistance too often limit the success of the treatment. DNA damage-related alternative splicing (AS) profoundly affects the transcriptome. Given AS involvement in cisplatin-induced cellular responses, identify key regulators in cisplatin-induced AS could lead to new target therapeutic approaches. In this work, we used the exclusion of exons 4-5 of COASY, a robust event detected in cisplatin-treated cells, as reporter. An siRNA screening targeting 56 RNA binding proteins identified RBM39 as a positive regulator of this event in non-treated cells. Following cisplatin treatment, RBM39 depletion enhances exons 4-5 skipping, while c-JUN (known to bind to RBM39) depletion reduced it. We observed by immunoprecipitation and gPCA that the interaction between c-JUN and RBM39 was cisplatin-dependent and RNA-/DNA-independent. Importantly, c-JUN TAD phosphorylation, essential for AP-1 transcriptional activity, was not required to control spliceosome specificity. These observations, combined with the reduced recruitment of RBM39 on COASY transcripts in cisplatin-treated cells, led us to hypothesize a moonlighting role of c-JUN, where it controls the spliceosome specificity independently of its transcriptional potential via direct binding to RBM39. Transcriptome analysis in MCF7 cells depleted in c-Jun or RBM39, treated or not by cisplatin, identified hundreds of skipped exons induced by cisplatin in control cells dependent of RBM39. Among these events 80% were reduced when c-JUN was downregulated suggesting a large-scale regulation mechanism of the spliceosome by these proteins. Functionally, COASYΔE4-5 downregulation modifies the mitochondrial ultrastructure.
Research center :
GIGA‐R - Giga‐Research - ULiège
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Lemaitre, Florence ;  Université de Liège - ULiège > GIGA Molecul. Biolog. of Diseases - Gene Expression & Cancer
Chakrama, Fatima
Dequiedt, Franck  ;  Université de Liège - ULiège > Département des sciences de la vie > Génétique et biologie moléculaires animales
Chabot, Benoit
Klinck, R
Colige, Alain ;  Université de Liège - ULiège > GIGA Cancer - Connective Tissue Biology
Piette, Jacques
Lambert, Charles
Habraken, Yvette ;  Université de Liège - ULiège > GIGA Molecul. Biolog. of Diseases - Gene Expression & Cancer
Language :
English
Title :
c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds
Alternative titles :
[fr] c-Jun et RBM39 co-régulent l'épissage alternatif induit par les composés chimiothérapeutiques
Publication date :
15 April 2021
Event name :
Joint Course on Post-Transcriptional Gene Regulation and Genome Instability
Event organizer :
Institut Curie
Event place :
Paris, France
Event date :
du 12 avril 2021 au 20 avril 2021
By request :
Yes
Audience :
International
Available on ORBi :
since 31 May 2021

Statistics


Number of views
126 (16 by ULiège)
Number of downloads
4 (3 by ULiège)

Bibliography


Similar publications



Contact ORBi